
Negotiating a licence with the University
Does your organisation want to negotiate an IP or technology licence with the University? Learn about technology transfer, IP, fees and regulations.
Multi-drug resistant (MDR) bacteria are a threat to human health. Image: Medical illustration of drug-resistant, Neisseria gonorrhoeae bacteria.
Partner with us to speed up the development of SNAPP anti-bacterial technology. Explore opportunities for licensing or direct investment.
University of Melbourne researchers have created star-shaped polypeptides. These are Structurally Nanoengineered Antimicrobial Peptide Polymers, or SNAPPs. They have anti-bacterial properties, including against MDR bacteria.
SNAPPs also have adjuvant activity, improving the efficiency of existing antibiotics.
Multi-drug resistant (MDR) bacteria are a threat to human health. The development of novel anti-bacterial therapies is a global health priority.
Proof-of-concept has been achieved using various in vitro microscopy and bioassay studies. These show SNAPPs’ antimicrobial activity, mode of action and low toxicity.
Shereen Tan
Phone +61 3 9035 6020
Star-shaped Polypeptides flyer (PDF)
Image by Medical Illustrator Alissa Eckert. Photo by US Centers for Disease Control and Prevention (CDC) on Unsplash.
Does your organisation want to negotiate an IP or technology licence with the University? Learn about technology transfer, IP, fees and regulations.
Partner with the University of Melbourne. Join a community where the world’s best minds help solve the biggest global challenges of our time.
Collaboration can create new intellectual property (IP). Discover the principles that guide how the University manages IP with its partners.
Discover what it’s like to work with the University of Melbourne. You’ll have a dedicated relationship manager and a flexible, pragmatic agreement.